Cardiac Arrhythmia: Possible Complication from Treatment with Cisplatin
Open Access
- 1 April 1986
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 72 (2) , 201-204
- https://doi.org/10.1177/030089168607200215
Abstract
Cardiotoxicity is rarely observed during cisplatin chemotherapy. A possible synergistic toxic effect of cisplatin with etoposide on cardiac electrical activity is discussed. A case of a 60-year-old woman with squamous cell lung carcinoma who developed paroxysmal supraventricular tachycardia during cisplatin chemotherapy is reported. The potential cardiotoxicity should be considered when cisplatin is combined with other cardiotoxic agents or used in patients with cardiac disease.This publication has 21 references indexed in Scilit:
- Cardiotoxicity of antitumor agentsProgress in Cardiovascular Diseases, 1984
- Supraventricular TachycardiaOncology, 1984
- Efficacy and cost of cardiac monitoring in patients receiving doxorubicinCancer, 1982
- Review of etoposide single-agent activityCancer Treatment Reviews, 1982
- Etoposide—chemistry, preclinical and clinical pharmacologyCancer Treatment Reviews, 1982
- Dose-effect and structure-function relationships in doxorubicin cardiomyopathyAmerican Heart Journal, 1981
- CARDIOTOXICITY OF 5-FLUOROURACILThe Lancet, 1977
- MYOCARDIAL INFARCTION: A COMPLICATION OF VINCRISTINE TREATMENT?The Lancet, 1976
- 5-FLUOROURACIL AND ANGINAThe Lancet, 1975
- cis-Dichlorodiammineplatinum(II) (NSC-119 875): Preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and miceToxicology and Applied Pharmacology, 1973